Abstract:Background: Cisplatin (CDDP) is a widely used cancer therapy drug that exhibits major side effects in normal tissues, such as nephrotoxicity in kidneys. The Nrf2 signaling pathway, a regulator of mitochondrial dysfunction, oxidative stress and inflammation, is a potential therapeutic target in CDDP-induced nephrotoxicity. Methods: We explored the underlying mechanisms in wild-type (WT) and Nrf2-/- mice on CDDP-induced renal dysfunction in vivo. As Daphnetin (Daph) is a Nrf2 activator, here, we assessed the effects of Daph against CDDP-induced nephrotoxicity using HK-2 cells. Results: We found that Nrf2 deficiency aggravated CDDP-induced nephrotoxicity, and Daph treatment significantly ameliorated the renal injury characterized by biochemical markers in WT mice and reduced the CDDP-induced cell damage. In terms of the mechanism, Daph upregulated the SIRT1 and SIRT6 expression in vivo and in vitro. In addition, Daph activated Nrf2 translocation and the expression of its regulated antioxidant enzymes HO-1 and NQO1, whereas it inhibited NOX4 expression, thus decreasing oxidative stress and mitochondrial dysfunction. Moreover, Daph attenuated CDDP-induced activation of HMGB1 and the phosphorylation of JNK, p38, ERK and NF-κB to suppress inflammation, as well as decreased CDDP-induced upregulation of cleaved caspase-3, p53 and the Bax/Bcl2 ratio to inhibit apoptosis. Notably, the protective effects of Daph in WT mice were completely abrogated in Nrf2 -/- mice. Moreover, Daph enhanced, rather than attenuated, the tumoricidal effect of CDDP. Conclusions: Our findings indicate the protective effect of Daph on CDDPinduced nephrotoxicity by SIRT1 and SIRT6 mediated-Nrf2 activation which regulates inflammation, mitochondrial dysfunction and apoptosis. Funding Statement: This work was supported by the National Natural Science Foundation of China (Grant No. 81603174) and the General Financial Grant from the China Postdoctoral Science Foundation (Grant No. 168847).Declaration of Interests: The authors declare that they have no competing interestsEthics Approval Statement: All animal studies were reviewed and approved by the Animal Welfare and Research Ethics Committee of Jilin University.

Overexpressed SIRT6 Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting ERK1/2 Signaling

SIRT6 Suppresses Mitochondrial Defects and Cell Death Via the NF-κB Pathway in Myocardial Hypoxia/reoxygenation Induced Injury.

Pharmacological Activation of Sirt1 Ameliorates Cisplatin-Induced Acute Kidney Injury by Suppressing Apoptosis, Oxidative Stress, and Inflammation in Mice

Roles of SIRT6 in Kidney Disease: a Novel Therapeutic Target.

Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling

Sirt6 Attenuates Hypoxia‐induced Tubular Epithelial Cell Injury Via Targeting G2/M Phase Arrest

Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury via SIRT6-Mediated Autophagy Activation

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling

Activated SIRT1 and SIRT6 by Nrf2 Activator Attenuated Cisplatin-Induced Acute Nephrotoxicity in Mice

The Deacetylase Sirtuin 6 Protects Against Kidney Fibrosis by Epigenetically Blocking Β-Catenin Target Gene Expression.

Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.

Ellagic acid ameliorates cisplatin-induced acute kidney injury by regulating inflammation and SIRT6/TNF-α signaling

SIRT6 As a Key Event Linking P53 and NRF2 Counteracts APAP-induced Hepatotoxicity Through Inhibiting Oxidative Stress and Promoting Hepatocyte Proliferation

2-Methylquinazoline Derivative 23BB As a Highly Selective Histone Deacetylase 6 Inhibitor Alleviated Cisplatin-Induced Acute Kidney Injury.

Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway

Daphnetin Attenuated Cisplatin-Induced Acute Nephrotoxicity with Enhancing Antitumor Activity of Cisplatin by Upregulating SIRT1/SIRT6-Nrf2 Pathway

SIRT1 Mediates Effects of FGF21 to Ameliorate Cisplatin-Induced Acute Kidney Injury

Sirt3 Modulates Fatty Acid Oxidation and Attenuates Cisplatin-Induced AKI in Mice.

Porous Se@SiO2 Nanospheres Attenuate Cisplatin-Induced Acute Kidney Injury Via Activation of Sirt1.

p53/sirtuin 1/NF-κB Signaling Axis in Chronic Inflammation and Maladaptive Kidney Repair After Cisplatin Nephrotoxicity

Ameliorative effects of miR-186 on cisplatin-triggered acute kidney injury via targeting ZEB1